ReviewTranslational pediatrics2024
Efficacy of prophylactic sodium valproate in pediatric migraines: a systematic review of randomized clinical studies.
Review in Translational pediatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prophylactic efficacy and safety of valproate versus topiramate for migraine: a systematic review.BMC neurology · 2026Pooled it
- Therapeutic Overlap Between Bipolar Disorder and Migraine: A Systematic Review of Pharmacological Trials.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Migraine is a neurological disorder that is chronic and presents with episodes of paroxysmal features consisting of multiphase attacks of head pain, along with other symptoms related to neurological dysfunction such as sensitivity to movement, photophobia, phonophobia, nausea, and vomiting. Antiseizure medications are frequently used for the treatment of migraine. Of the antiseizure medications, sodium valproate and topiramate have received approval from the Food and Drug Administration (FDA) to prevent adult migraine. More recently, topiramate gained approval for pediatric migraine, whereas sodium valproate did not. Nevertheless, the off-label utilization of these drugs for pediatric migraine is widespread. The objective of this review is to assess the prophylactic efficacy of sodium valproate in the management of pediatric migraines. Methods: The protocol of this study was registered with PROSPERO (CRD42023454491). Therefore, this systematic review aims to assess the efficacy of sodium valproate as a prophylaxis treatment for pediatric migraine. A comprehensive unrestricted search of indexed databases, including PubMed, Embase, Web of Science, and Cochrane, was conducted without any restrictions until May 2024. Results: The review included five randomized controlled trials (RCTs). Among these, two exhibited a generally low risk of bias (RoB), while the remaining RCTs demonstrated a high risk for bias. Conclusions: The findings from the current evidence suggest no significant differences in the effectiveness of sodium valproate compared to other frequently used medications in preventing pediatric migraine. Subsequent studies should maintain uniformity in their protocol design and introduce blinding methodologies across outcome assessment, participants, and researchers. These strategies hold significant importance in mitigating potential sources of bias.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.